VENTOLIN
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Apr 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
VENTOLIN by GSK is 2 -adrenergic receptors compared with isoproterenol. Approved for exercise-induced bronchospasm in adult, older. First approved in 1992.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENTOLIN is a rescue inhaler solution administered via inhalation, developed by GSK and approved in 1992. The product treats acute respiratory symptoms through bronchodilation, delivering rapid relief to patients experiencing airway constriction. It is a foundational therapy in respiratory care and remains a standard-of-care acute treatment.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); team focus likely shifting toward lifecycle extension, generic preparation, or transition strategies.
Mechanism of Action
2 -adrenergic receptors compared with isoproterenol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50%…
Indications (2)
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.